score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.43700000000000006	270.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	152.0	0.4803	1.0	NRAS p.Q61R (Missense)	1.0	MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S438N	0.3793	116.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143													0	0.0	0.0	0.0	GATA3 p.S438N (Missense)		MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat123		
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1034L	0.331	142.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0	163.0	0.4663	1.0	CDK12 p.P1034L (Missense)	0.0	MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Biologically Relevant				Rearrangement	ERBB3	Fusion	MALAT1--ERBB3			0.0	0.0																					0				MALAT1--ERBB3 Fusion		MEL-IPI_Pat123		
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P437S	0.3824	102.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.P437S (Missense)		MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1946S	0.4514	175.0	0.0	0.0																					0	241.0	0.4025	1.0	NF1 p.L1946S (Missense)		MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P473S	0.4519	135.0	0.0	0.0																					0	0.0	0.0	0.0	EWSR1 p.P473S (Missense)		MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P473Q	0.4412	136.0	0.0	0.0																					0	0.0	0.0	0.0	EWSR1 p.P473Q (Missense)		MEL-IPI_Pat123	MEL-IPI_Pat123-Tumor-SM-5X2R1	MEL-IPI_Pat123-Normal-SM-5VWHL
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat123		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.832																									0				COSMIC Signature (version 2) 7 (83%)		MEL-IPI_Pat123		
